Preoperative (chemo)immunotherapy for stage III NSCLC
Started by seper
Get help with your application
Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.
I am aware of two published trials:
SAKK 16/14:
pubmed.ncbi.nlm.nih.gov
and
NADIM:
pubmed.ncbi.nlm.nih.gov
As far I know, these are the only two trials looking at stage III NSCLC specifically. There are other trials too, but they evaluated a wider spectrum of disease, from stage I to stage III.
SAKK 16/14:
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial - PubMed
The addition of perioperative durvalumab to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer is safe and exceeds historical data of chemotherapy alone with a high MPR and an encouraging 1-year EFS rate of 73%.
pubmed.ncbi.nlm.nih.gov
and
NADIM:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial - PubMed
Bristol-Myers Squibb, Instituto de Salud Carlos III, European Union's Horizon 2020 research and innovation programme.
pubmed.ncbi.nlm.nih.gov
As far I know, these are the only two trials looking at stage III NSCLC specifically. There are other trials too, but they evaluated a wider spectrum of disease, from stage I to stage III.
Medoncs trying to take away lung from us now?
Advertisement - Members don't see this ad
It may happen for resectable stage IIIA. The pCR rates are quite high with neoadjuvant IO + chemotherapy.
Adjuvant IO is also going to become s.o.c. likely within the next couple of years for patients with resected stage II-IIIA (on top or without adjuvant chemotherapy), so medoncs are likely to extrapolate that if it works in the adjuvant setting it is going to work in the neoadjuvant setting too.
We don't typically operate on Stage III anyways (unless incidental pN2 disease found after surgery) and I wasn't keen on pre-op in those patients to begin with.
Our thoracic surgeon was going off on some phase 2 trial at mskcc and how he sees it opening up more stage 3 to surg. He also thinks he will be giving the io. On a separately depressing note, the company making nav bronch is trialing an attachment for ablating tumors. Our guys can already deploy sbrt fiducials in very peripheral tumors.
Last edited:
Wasn’t IO recently approved w/postop chemo? Up until then, only chance for stage 3 pt to get IO was with pacific.
Last edited:
pCR is something med oncs love. Look at breast cancer, for instance, and how they are pushing for it there. The same goes for TNT in rectal cancer (soon without RT, likely).
Give the med oncs data on good pCR rates and they will push for that kind of treatment.
You must not have a med onc who tries to refer N3 disease to thoracic surgery for "curative" intent in an 'academic" practice. - Sigh... Its probably just me that I have to try to stop this every time.
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
CheckMate -816 is the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in the neoadjuvant setting of non-small cell lung cancer Positive results reinforce the improved efficacy seen with Opdivo-based...
Increased the pCR ten-fold? Whoa.Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
CheckMate -816 is the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in the neoadjuvant setting of non-small cell lung cancer Positive results reinforce the improved efficacy seen with Opdivo-based...bit.ly
These pCR rates are not that different than the below, but I would chose the IO versus the below personally.
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) - PubMed
This combined-modality approach is feasible and is associated with high rates of complete resection and pathologic CR in both T3 and T4 tumors. Local control and overall survival seem markedly improved relative to previous studies of radiation plus resection.
pubmed.ncbi.nlm.nih.gov
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial - PubMed
Deescalation of radiotherapy to 30 Gy on the basis of intratreatment hypoxia imaging was feasible, safe, and associated with minimal toxicity. A DNA repair defect identified by WGS was predictive of response. Intratherapy personalization of chemoradiotherapy may facilitate marked deescalation of...
pubmed.ncbi.nlm.nih.gov
a 22 pt med onc trial gets you nejm
Absolutely. The IO is having a systemic effect as well. It also seems to work if pdl< 1%Increased the pCR ten-fold? Whoa.
These pCR rates are not that different than the below, but I would chose the IO versus the below personally.
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) - PubMed
This combined-modality approach is feasible and is associated with high rates of complete resection and pathologic CR in both T3 and T4 tumors. Local control and overall survival seem markedly improved relative to previous studies of radiation plus resection.
Last edited:
Or any different that this one:Increased the pCR ten-fold? Whoa.
These pCR rates are not that different than the below, but I would chose the IO versus the below personally.
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) - PubMed
This combined-modality approach is feasible and is associated with high rates of complete resection and pathologic CR in both T3 and T4 tumors. Local control and overall survival seem markedly improved relative to previous studies of radiation plus resection.
Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer - PubMed
German Cancer Aid (Bonn, Germany).
pubmed.ncbi.nlm.nih.gov
Advertisement - Members don't see this ad
Similar threads
